2023 was the most memorable year on record for obesity. The American Academy of Pediatrics recognized the complex, multifactorial nature of obesity and the broad range of treatments necessary to care for pediatric patients. The first-ever triple agonist and high-potency oral GLP1 agonist was introduced with unprecedented results.

中文翻译：

---

肥胖管理的新时代

2023 年是有记录以来肥胖最值得纪念的一年。美国儿科学会认识到肥胖的复杂性、多因素性质以及护理儿科患者所需的广泛治疗方法。首款三重激动剂和高效口服 GLP1 激动剂的推出取得了前所未有的效果。